Interruption of the effects of gastrin as a potential target in the treatment of colorectal cancer, using several different approaches, such as the gastrin (CCK-B or CCK-2) receptor antagonists, proglumide and benotript, has been assessed (Watson et al, 1992a,b). This evidence concerns the gene CCKBR and colorectal cancer.